Financial Comparison: Saratoga Investment (NYSE:SAR) versus Advanced Medical Isotope (OTCMKTS:RDGL)

Saratoga Investment (NYSE:SAR) and Advanced Medical Isotope (OTCMKTS:RDGL) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Earnings and Valuation

This table compares Saratoga Investment and Advanced Medical Isotope”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Saratoga Investment	$148.85 million	2.39	$28.09 million	$2.47	9.03
Advanced Medical Isotope	$30,000.00	1,288.23	-$2.91 million	N/A	N/A

Saratoga Investment has higher revenue and earnings than Advanced Medical Isotope.

Analyst Recommendations

This is a breakdown of recent recommendations for Saratoga Investment and Advanced Medical Isotope, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Saratoga Investment	0	5	0	0	2.00
Advanced Medical Isotope	0	0	0	0	0.00

Saratoga Investment currently has a consensus price target of $24.25, suggesting a potential upside of 8.74%. Given Saratoga Investment’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Saratoga Investment is more favorable than Advanced Medical Isotope.

Volatility & Risk

Saratoga Investment has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Insider & Institutional Ownership

19.1% of Saratoga Investment shares are owned by institutional investors. 10.0% of Saratoga Investment shares are owned by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Saratoga Investment and Advanced Medical Isotope’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Saratoga Investment	27.19%	10.23%	3.30%
Advanced Medical Isotope	-6,401.92%	N/A	-139.36%

Summary

Saratoga Investment beats Advanced Medical Isotope on 8 of the 11 factors compared between the two stocks.

About Saratoga Investment

Saratoga Investment Corp. is a business development company specializing in leveraged and management buyouts, acquisition financings, growth financings, recapitalization, debt refinancing, and transitional financing transactions at the lower end of middle market companies. It structures its investments as debt and equity by investing through first and second lien loans, mezzanine debt, co-investments, select high yield bonds, senior secured bonds, unsecured bonds, and preferred and common equity. The firm prefers to invest in aerospace, automotive aftermarket and services, business products and services, consumer products and services, education, environmental services, industrial services, financial services, food and beverage, healthcare products and services, logistics, distribution, manufacturing, restaurants services, food services, software services, technology services, specialty chemical, media and telecommunications. It seeks to invest in the United States. The firm primarily invests $5 million to $50 million in companies having EBITDA of $2 million or greater and revenues of $8 million to $250 million. The firm prefer to take a majority stake. It invests through direct lending as well as participation in loan syndicates. The firm was formerly known as GSC Investment Corp. Saratoga Investment Corp. was formed on 2007 and is based in New York, New York with an additional office in Florham Park, New Jersey.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.